VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will oversee the advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company's oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA accelerates its pipeline of bispecific T cell engagers and bispecific ADCs, leveraging its suite of transformative technologies guided by quality-by-design principles. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For more details, the full press release is available at https://nnw.fm/cR1RS. VERAXA's latest news and updates can be accessed via its newsroom at https://ibn.fm/VRXA.
This appointment is significant as it signals VERAXA's commitment to advancing its BiTAC platform into clinical development, potentially offering new treatment options for patients with solid tumors. The company's focus on next-generation antibody-based therapeutics positions it in a competitive landscape where bispecific antibodies are gaining traction for their ability to engage immune cells directly at tumor sites.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in VERAXA's SEC filings. Investors should not place undue reliance on these statements, as actual results may differ materially.
